Menu Search
Equities

Indivior Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2IVB:MUN

Indivior Pharmaceuticals Inc

Actions
  • Price (EUR)27.80
  • Today's Change0.00 / 0.00%
  • Shares traded50.00
  • 1 Year change+194.18%
  • Beta1.1493
Data delayed at least 15 minutes, as of Jan 26 2026 07:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.

  • Revenue in USD (TTM)1.18bn
  • Net income in USD122.00m
  • Incorporated2025
  • Employees1.03k
  • Location
    Indivior Pharmaceuticals Inc10710 Midlothian TurnpikeSuite 125, North ChesterfieldDOVER 23235United StatesUSA
  • Phone+1 (804) 379-1090
  • Websitehttps://www.indivior.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.